What Do Analysts Think About UniQure (QURE)?
UniQure (NASDAQ:QURE) is one of the best small cap stocks to buy with huge upside potential.
Uniqure N.v. (QURE)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 4,444,444 | $259,422,196 | +23% | 3.35% |
| 2. | EcoR1 Capital Oleg Nodelman | 3,988,971 | $232,836,237 | 11.17% | |
| 3. | 683 Capital Partners Ari Zweiman | 1,070,000 | $62,455,900 | -17% | 3.26% |
| 4. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,007,492 | $58,807,308 | -51% | 2.04% |
| 5. | Eversept Partners Kamran Moghtaderi | 877,373 | $51,212,262 | 3.53% |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.30 | 15,594 | $425,716.20 | 40,145 | 2025-11-06 | Filing | |
| $27.22 | 15,840 | $431,164.80 | 55,739 | 2025-11-06 | Filing | |
| $30.33 | 17,810 | $540,177.30 | 20,439 | 2025-11-04 | Filing | |
| $30.34 | 11,000 | $333,740.00 | 20,439 | 2025-11-04 | Filing | |
| $30.36 | 10,000 | $303,600.00 | 20,439 | 2025-11-04 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 606,923 | $14,523,667 | 0.02% | |
| 2. | 85 | $2,034 | 0% | |
| 3. | 64,326 | $1,539 | 0% | |
| 4. | 8 | $191 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
12 Small Cap Stocks to Buy with Huge Upside Potential
Talking about rotation in the market, she expects the trend to continue for a while, with the capital basically moving from the high multiple mega cap winners towards small caps, cyclicals, and the international...
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch
UniQure (NASDAQ:QURE) is one of the stocks that will double in 2026.
7 Hidden Multibagger Stocks to Invest In
Multibaggers often take the limelight because of their stellar returns, but it isn’t always easy to catch these multibaggers while they are in the process of generating these returns.
uniQure N.V. (QURE): A Bear Case Theory
We came across a bearish thesis on uniQure N.V. on augur’s substack. In this article, we will summarize the bulls’ thesis on QURE.
William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty
uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to invest in. William Blair reaffirmed its Market Perform rating for uniQure N.V.
9 Oversold Biotech Stocks to Invest In
Biotech companies are making a solid comeback following an extended slump as investors shift their focus back to value and healthcare.
Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3
Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Hottest Small Cap Stocks to Buy Now
On November 12, Scott Chronert, Citi's U.S. equity strategist, appeared on a CNBC Television interview to discuss his bullish case for small- and mid-cap stocks.
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences
In an updated report, uniQure NV (NASDAQ:QURE) said that it would participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, Massachusetts, on Wednesday, November 12, as well...
Hedge Fund Resource Center Billionaire Hedge Funds
